Ultra makes plant-based, sugar-free oral pouches formulated with paraxanthine (Enfinity®), L-theanine, Alpha GPC, B-vitamins, and ginseng to deliver a discreet cognitive boost without nicotine or caffeine. Launched in May 2025, the company has moved 1 million cans in its first six months on the market, becoming the world’s top-selling nicotine-free pouch brand. Ultra targets high performers seeking focus during deep work, training, travel, or evening wind-downs and also appeals to consumers who have never used nicotine products. The product sits at the intersection of the fast-growing $5.4 billion oral pouch category and the broader demand for cleaner performance enhancers. Early surveys show roughly 30 % of buyers are new to pouch formats, highlighting incremental market potential beyond nicotine substitution. Management plans to channel new capital into U.S. hiring, expanded retail distribution, and a wider product roadmap that will introduce additional formats and potency profiles over time.

Total raised

$11M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2026